Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

155P - Eligibility for lung cancer screening among patients diagnosed with lung cancer in Greece

Date

31 Mar 2023

Session

Poster Display session

Presenters

Maximilian Anagnostakis

Citation

Journal of Thoracic Oncology (2023) 18 (4S): S121-S128.
<article-id>elcc_Ch07

Authors

M.I. Anagnostakis1, E. Panagiotou2, N. Salonitis2, A. Skoura2, D. Setatoglou2, A. Karachaliou2, N. Syrigos2, L. Stournara2, M. Mani2, I. Vathiotis2

Author affiliations

  • 1 Athens/GR
  • 2 Sotiria Thoracic Diseases Hospital of Athens, Athens/GR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 155P

Background

Implementation of lung cancer screening with annual low-dose computed tomography (CT) scans has resulted in significant improvement in disease-specific and overall survival in large prospective studies. Little is known about the proportion of patients with lung cancer that would be eligible for participation in screening programs in the real world.

Methods

We performed a retrospective chart review of patients with lung cancer diagnosed at Sotiria General Hospital for Chest Diseases, Athens, Greece, between January 2016 and December 2018. Descriptive statistics were utilized to calculate the proportion of patients that would be eligible for lung cancer screening and chi-squared test to assess for associations between baseline patient characteristics and lung cancer screening criteria. All hypothesis testing was conducted at a two-sided significance level of α = 0.05.

Results

898 patients were screened; 750 patients were eligible for study inclusion. The median age at diagnosis was 67 years (range 34–93). Among study participants, 73.2%, 21.5%, and 5.3% were current, former, and never smokers, respectively. Histotypes were distributed as follows: adenocarcinoma, 42.7%; squamous cell carcinoma, 30.8%; small cell lung cancer, 14.7%; large cell neuroendocrine carcinoma, 3.6%; not otherwise specified, 4.1%; other, 4.0%%. Targetable driver alterations were identified in 16.9% of patients (39/231). The proportion of patients eligible for lung cancer screening at the time of diagnosis ranged according to screening criteria applied (NLST: 60.3%, USPSTF: 78.7%, NELSON: 64.4%). Baseline characteristics associated with qualification for screening according to the NLST criteria were squamous (OR, 2.23; 95% CI, 1.57–3.19; p < 0.00001) and small cell (OR, 2.10; 95% CI, 1.34–3.34; p = 0.001) histology and lack of targetable driver alterations (OR, 3.39; 95% CI, 1.49–8.54; p = 0.003).

Conclusions

Most patients with lung cancer qualify for screening at the time of diagnosis; baseline characteristics directly linked with smoking appear significantly associated with screening eligibility. This underlines the need for more personalized screening approaches in the absence of substantial smoking history.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.